Fernando Chernomordik

Dr. Fernando Chernomordik


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2016 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
FCFernando Chernomordik
Fernando Chernomordik
ASAvi Sabbag
Avi Sabbag
BTBoaz Tzur
Boaz Tzur
EKEran Kopel
Eran Kopel
RGRonen Goldkorn
Ronen Goldkorn
RKRobert Klempfner
Robert Klempfner
Utilization of cardiac rehabilitation is suboptimal. The aim of the study was to assess referral trends over the past decade, to identify predictors for referral to a cardiac rehabilitation program, and to evaluate the association with one-year mortality in a large national registry of acute coronary syndrome patients. Data were extracted from the Acute Coronary Syndrome Israeli Survey national surveys between 2006–2013. A total of 6551 patients discharged with a diagnosis of acute coronary syndrome were included. Referral to cardiac rehabilitation following an acute coronary syndrome increased from 38% in 2006 to 57% in 2013 (p for trend < 0.001). Multivariate modeling identified the following independent predictors for non-referral: 2006 survey, older age, female sex, past stroke, heart or renal failure, prior myocardial infarction, minority group, and lack of in-hospital cardiac rehabilitation center (all p < 0.01). Kaplan-Meier survival analyses showed one-year survival rates of 97% vs 92% in patients referred for cardiac rehabilitation as compared to those not referred (log-rank p < 0.01). Multivariate analysis showed that referral for cardiac rehabilitation was associated with a 27% mortality risk reduction at one-year follow-up (p = 0.03). Consistently, a 32% lower one-year mortality risk was evident in a propensity score matched group of 3340 patients (95% confidence interval 0.48–0.95, p = 0.02). Over the past decade there was a significant increase in cardiac rehabilitation referral following an acute coronary syndrome. However, cardiac rehabilitation is still under-utilized in important high-risk subsets of this population. Patients referred to cardiac rehabilitation have a lower adjusted mortality risk.

1 July 2016 in The American Journal of Cardiology
Verified
Journal Article
Closed access
FCFernando Chernomordik
Fernando Chernomordik
ABAnat Berkovitch
Anat Berkovitch
ESEhud Schwammenthal
Ehud Schwammenthal
IGIlan Goldenberg
Ilan Goldenberg
DRDavid Rott
David Rott
RKRobert Klempfner
Robert Klempfner

1 March 2022 in Journal of Cardiology
Verified
Journal Article
Closed access
Amitai SegevAmitai Segev
Amitai Segev
EIEdward Itelman
Edward Itelman
RBRoy Beigel
Roy Beigel
GSGad Segal
Gad Segal
FCFernando Chernomordik
Fernando Chernomordik
AGAvishay Grupper
Avishay Grupper

29 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IMIsrael Mazin
Israel Mazin
FCFernando Chernomordik
Fernando Chernomordik
PFPaul Fefer
Paul Fefer
SMShlomi Matetzky
Shlomi Matetzky
RBRoy Beigel
Roy Beigel
It is estimated that in the past two decades the number of patients diagnosed with diabetes mellites (DM) has doubled. Despite significant progress in the treatment of cardiovascular disease (CVD), including novel anti-platelet agents, effective lipid-lowering medications, and advanced revascularization techniques, patients with DM still are least twice as likely to die of cardiovascular causes compared with their non-diabetic counterparts, and current guidelines define patients with DM at the highest risk for atherosclerotic cardiovascular disease and major adverse cardiovascular events (MACE). Over the last few years, there has been a breakthrough in anti-diabetic therapeutics, as two novel anti-diabetic classes have demonstrated cardiovascular benefit with consistently reduced MACE, and for some agents, also improvement in heart failure status as well as reduced cardiovascular and all-cause mortality. These include the sodium-glucose cotransporter-2 inhibitors and the glucagon-like peptide-1 receptor agonists. The benefits of these medications are thought to be derived not only from their anti-diabetic effect but also from additional mechanisms. The purpose of this review is to provide the everyday clinician a detailed review of the various agents within each class with regard to their specific characteristics and the effects on MACE and cardiovascular outcomes.

1 April 2014 in JACC
Verified
Journal Article
Closed access
DMDiego Medvedofsky
Diego Medvedofsky
RKRobert Klempfner
Robert Klempfner
PFPaul Fefer
Paul Fefer
FCFernando Chernomordik
Fernando Chernomordik
AHAshraf Hamdan
Ashraf Hamdan
ASAmit Segev
Amit Segev

2 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AFAlexander Fardman
Alexander Fardman
FCFernando Chernomordik
Fernando Chernomordik
RBRoy Beigel
Roy Beigel
Cardiovascular disease (CVD) remains the most common cause of morbidity and mortality worldwide